The Lancet publishes Capricor's phase 3 DMD therapy trial results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. APLD
3. STZ
4. RMR
5. DVN
6. CRGY
7. ZETA
8. ARGX
9. SPY
10. ANGO

Go back to The Lancet publishes Capricor's phase 3 DMD therapy trial results

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

July 29, 2026 10:05 AM EDT

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings--

--Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit--

--Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026--

SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) --... More